Patent US6521455B2 successfully refreshed from Google Patents.
US6521455B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nucleic acid molecule encoding a transport protein
Assignee: Marie Curie Cancer Care
•
Filing: 2001-01-31
•
Granted: 2003-02-18
•
Expires: 2021-01-31
Abstract
Abstract The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.
Inventors
- 👤 Peter Francis Joseph O'Hare
- 👤 Gillian Daphne Elliott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 22:35
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/87; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K48/00; C07K2319/00; C07K2319/01; C07K2319/10; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16622
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
68 words
A recombinant nucleic acid molecule encoding a fusion protein of formula A-B, wherein A comprises a transport-active material selected from the group consisting of a herpesviral VP22 protein, a polypeptide comprising the C-terminal 34 amino acid residues of a herpesviral VP22 protein, and a transport active portion of a herpesviral VP22 protein, and B comprises a heterologous polypeptide sequence that is desired to be delivered into a cell.
Claim 2
Dependent Claim
68 words
A recombinant nucleic acid molecule encoding a fusion protein of formula A-B, wherein A comprises a transport-active material selected from the group consisting of a herpesviral VP22 protein, a polypeptide comprising the C-terminal 34 amino acid residues of a herpesviral VP22 protein, and a transport active portion of a herpesviral VP22 protein, and B comprises a heterologous polypeptide sequence that is desired to be delivered into a cell.
Claim 3
Dependent Claim
18 words
The recombinant nucleic acid molecule of claim 1 , wherein B comprises a green fluorescent protein polypeptide sequence.
Claim 4
Dependent Claim
15 words
A nucleic acid vector including a recombinant nucleic acid molecule according to claim 1 .
Claim 5
Dependent Claim
30 words
A nucleic acid vector according to claim 3 wherein the nucleic acid vector is a viral vector selected from the group consisting of herpesvirus vectors, adenovirus vectors and retrovirus vectors.
Claim 6
Dependent Claim
15 words
A nucleic acid vector according to claim 4 where the virus is a disabled virus.
Claim 7
Dependent Claim
14 words
An isolated host cell comprising a nucleic acid molecule according to claim 1 .
Claim 8
Dependent Claim
15 words
The host cell of claim 6 , where the host cell is a mammalian cell.
Claim 9
Independent Claim
81 words
A method of introducing a desired peptide into a population of cells, the method comprising introducing into one or more cells of the population a nucleic acid molecule which encodes a fusion protein comprising (i) an amino acid sequence of a transport-active material selected from the group consisting of a herpesviral VP22 protein and a transport-active portion of a herpesviral VP22 protein, and (ii) an amino acid sequence of a desired peptide associated with the transport-active material as a fusion partner.
Claim 10
Independent Claim
81 words
A method of introducing a desired peptide into a population of cells, the method comprising introducing into one or more cells of the population a nucleic acid molecule which encodes a fusion protein comprising (i) an amino acid sequence of a transport-active material selected from the group consisting of a herpesviral VP22 protein and a transport-active portion of a herpesviral VP22 protein, and (ii) an amino acid sequence of a desired peptide associated with the transport-active material as a fusion partner.
Claim 11
Dependent Claim
32 words
The method of claim 8 , wherein the transport-active material comprises an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence as shown in SEQ ID NO:2.
Claim 12
Dependent Claim
13 words
The method of claim 8 , wherein said introducing is achieved by transfection.
Claim 13
Dependent Claim
13 words
The method of claim 8 , wherein said introducing is achieved by microinjection.
Claim 14
Dependent Claim
15 words
The method of claim 8 , wherein said introducing is achieved by liposome mediated transformation.
Claim 15
Dependent Claim
24 words
The method of claim 8 , wherein the nucleic acid molecule encoding a fusion protein is part of a genome of a recombinant virus.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2006-02-17 | 2006-08-19 | 2007-02-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2010-02-17 | 2010-08-19 | 2011-02-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2014-02-17 | 2014-08-19 | 2015-02-18 | $7700.00 | Window Closed / Lapsed |